Rebecca Strawbridge1, John Hodsoll2, Timothy R Powell3, Matthew Hotopf4, Stephani L Hatch5, Gerome Breen3, Anthony J Cleare4. 1. Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. Electronic address: Becci.strawbridge@kcl.ac.uk. 2. Department of Biostatistics, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. 3. Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. 4. Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; South London & Maudsley NHS Foundation Trust, London, UK. 5. Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Abstract
BACKGROUND: Treatment-resistant depression (TRD) contributes substantially to the burden of mood disorders and is undoubtedly an important subpopulation in whom there are clear unmet treatment needs. Despite a paucity of research focusing specifically on TRD, recent studies indicate that inflammatory activity may be particularly elevated in these patients. METHODS: 36 patients with TRD were investigated longitudinally before and after undertaking a specialist inpatient treatment program. 27 inflammatory proteins were compared between patients and a matched sample of non-depressed controls, as well as between treatment responders and non-responders. Treatment outcomes were calculated from depression severity scores before and after admission, and at a long-term follow-up 3-12 months after discharge. RESULTS: TRD patients had higher levels of numerous inflammatory proteins than controls, and elevated interleukins 6 and 8, tumour necrosis factor, c-reactive protein and macrophage inflammatory protein-1 were associated with poorer treatment outcomes. A separate set of proteins (either anti-inflammatory in nature or attenuated at baseline) showed increases during treatment, regardless of clinical response. Participants with the greatest elevations in inflammation tended to be older, more cognitively impaired and more treatment-resistant at baseline. LIMITATIONS: The small sample and large number of comparisons examined in this study must be taken into account when interpreting these results. CONCLUSIONS: However, this study provides empirical support for theories that more severe, chronic or treatment-resistant depressive disorders are associated with dysregulated inflammatory activity. If a predictor or predictors of response in TRD are established, improved and targeted care might be more reliably provided to this vulnerable population.
BACKGROUND: Treatment-resistant depression (TRD) contributes substantially to the burden of mood disorders and is undoubtedly an important subpopulation in whom there are clear unmet treatment needs. Despite a paucity of research focusing specifically on TRD, recent studies indicate that inflammatory activity may be particularly elevated in these patients. METHODS: 36 patients with TRD were investigated longitudinally before and after undertaking a specialist inpatient treatment program. 27 inflammatory proteins were compared between patients and a matched sample of non-depressed controls, as well as between treatment responders and non-responders. Treatment outcomes were calculated from depression severity scores before and after admission, and at a long-term follow-up 3-12 months after discharge. RESULTS: TRD patients had higher levels of numerous inflammatory proteins than controls, and elevated interleukins 6 and 8, tumour necrosis factor, c-reactive protein and macrophage inflammatory protein-1 were associated with poorer treatment outcomes. A separate set of proteins (either anti-inflammatory in nature or attenuated at baseline) showed increases during treatment, regardless of clinical response. Participants with the greatest elevations in inflammation tended to be older, more cognitively impaired and more treatment-resistant at baseline. LIMITATIONS: The small sample and large number of comparisons examined in this study must be taken into account when interpreting these results. CONCLUSIONS: However, this study provides empirical support for theories that more severe, chronic or treatment-resistant depressive disorders are associated with dysregulated inflammatory activity. If a predictor or predictors of response in TRD are established, improved and targeted care might be more reliably provided to this vulnerable population.
Authors: Daniel C McFarland; Allison J Applebaum; Erik Bengtsen; Yesne Alici; William Breitbart; Andrew H Miller; Christian Nelson Journal: Psychooncology Date: 2021-09-04 Impact factor: 3.955
Authors: Michael Fritz; Anna M Klawonn; Qingyu Zhao; Edith V Sullivan; Natalie M Zahr; Adolf Pfefferbaum Journal: J Neuroimmunol Date: 2020-08-26 Impact factor: 3.478
Authors: Alessio Squassina; Mirko Manchia; Claudia Pisanu; Raffaella Ardau; Carlo Arzedi; Alberto Bocchetta; Paola Caria; Cristina Cocco; Donatella Congiu; Eleonora Cossu; Tinuccia Dettori; Daniela Virginia Frau; Mario Garzilli; Elias Manca; Anna Meloni; Maria Antonietta Montis; Andrea Mura; Mariella Nieddu; Barbara Noli; Pasquale Paribello; Federica Pinna; Renato Robledo; Giovanni Severino; Valeria Sogos; Maria Del Zompo; Gian Luca Ferri; Caterina Chillotti; Roberta Vanni; Bernardo Carpiniello Journal: Neuropsychopharmacology Date: 2020-09-12 Impact factor: 7.853
Authors: Daniel C McFarland; Rebecca M Saracino; Andrew H Miller; William Breitbart; Barry Rosenfeld; Christian Nelson Journal: Future Oncol Date: 2020-12-11 Impact factor: 3.404
Authors: Lucia Carboni; Dennis J McCarthy; Bruno Delafont; Michele Filosi; Elena Ivanchenko; Emiliangelo Ratti; Susan M Learned; Robert Alexander; Enrico Domenici Journal: Transl Psychiatry Date: 2019-08-02 Impact factor: 6.222